Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939326 · ClinicalTrials.gov registry record · Phase 2
Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
A Phase 2 study of Glabellar Frown Lines (GL), sponsored by Bonti.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT02939326 is a Phase 2 study of Glabellar Frown Lines (GL) that has completed, run by Bonti. The registered enrollment target is 42 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT02939326, a Phase 2 study of Glabellar Frown Lines (GL), has completed, sponsored by Bonti.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar frown lines (GL).
Conditions Studied
Interventions
- DRUG EB-001 injection
- DRUG Placebo injection
Study Locations (2)
California
- Center For Dermatology Clinical Research, Inc. - Fremont
- Steve Yoelin, MD Medical Associates, INC. - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-07-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02939326
The ClinicalTrials.gov registry entry for NCT02939326 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bonti, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glabellar Frown Lines (GL) appearing as the primary indexed condition, and to 2 interventions - of which EB-001 injection is the first listed.
NCT02939326 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02939326 about?
NCT02939326 is a clinical study titled "Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines". To evaluate the safety and efficacy of EB-001 compared to placebo in subjects with glabellar frown lines (GL).
What is the current status of trial NCT02939326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2016-12. Estimated completion is 2017-07-12.
What conditions does trial NCT02939326 study?
This clinical trial studies the following conditions: Glabellar Frown Lines (GL).
What interventions are being tested in trial NCT02939326?
The interventions under investigation include: EB-001 injection (DRUG), Placebo injection (DRUG).
Who is sponsoring clinical trial NCT02939326?
This trial is sponsored by Bonti, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02939326 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.